260 related articles for article (PubMed ID: 12354446)
1. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor.
Jones SP; Gibson MF; Rimmer DM; Gibson TM; Sharp BR; Lefer DJ
J Am Coll Cardiol; 2002 Sep; 40(6):1172-8. PubMed ID: 12354446
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
Laufs U; Gertz K; Dirnagl U; Böhm M; Nickenig G; Endres M
Brain Res; 2002 Jun; 942(1-2):23-30. PubMed ID: 12031849
[TBL] [Abstract][Full Text] [Related]
3. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
Stalker TJ; Lefer AM; Scalia R
Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective effects of low-dose combination therapy with rosuvastatin and fasudil in the isolated rat heart.
Wu N; Li W; Lv Y; Shu W; Jia D
Pharmazie; 2014 Sep; 69(9):704-8. PubMed ID: 25272944
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats.
Ikeda Y; Young LH; Lefer AM
J Cardiovasc Pharmacol; 2003 Apr; 41(4):649-56. PubMed ID: 12658068
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation.
Bulhak A; Roy J; Hedin U; Sjöquist PO; Pernow J
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3158-63. PubMed ID: 17322412
[TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase.
Suh JW; Choi DJ; Chang HJ; Cho YS; Youn TJ; Chae IH; Kim KI; Kim CH; Kim HS; Oh BH; Park YB
J Korean Med Sci; 2010 Jan; 25(1):16-23. PubMed ID: 20052342
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion.
Weinberg EO; Scherrer-Crosbie M; Picard MH; Nasseri BA; MacGillivray C; Gannon J; Lian Q; Bloch KD; Lee RT
Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1802-9. PubMed ID: 15563531
[TBL] [Abstract][Full Text] [Related]
9. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Kilic U; Bassetti CL; Kilic E; Xing H; Wang Z; Hermann DM
Neuroscience; 2005; 134(3):901-6. PubMed ID: 16009498
[TBL] [Abstract][Full Text] [Related]
10. Statins and the response to myocardial injury.
Scalia R
Am J Cardiovasc Drugs; 2005; 5(3):163-70. PubMed ID: 15901204
[TBL] [Abstract][Full Text] [Related]
11. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts.
Di Napoli P; Taccardi AA; Grilli A; De Lutiis MA; Barsotti A; Felaco M; De Caterina R
Cardiovasc Res; 2005 Jun; 66(3):462-71. PubMed ID: 15914111
[TBL] [Abstract][Full Text] [Related]
12. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M
J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
Schäfer K; Kaiser K; Konstantinides S
Thromb Haemost; 2005 Jan; 93(1):145-52. PubMed ID: 15630505
[TBL] [Abstract][Full Text] [Related]
14. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level.
Bulhak AA; Gourine AV; Gonon AT; Sjöquist PO; Valen G; Pernow J
Acta Physiol Scand; 2005 Feb; 183(2):151-9. PubMed ID: 15676056
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury.
Ke D; Fang J; Fan L; Chen Z; Chen L
Coron Artery Dis; 2013 Jun; 24(4):334-41. PubMed ID: 23531479
[TBL] [Abstract][Full Text] [Related]
16. Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia.
Mayanagi K; Katakam PV; Gáspár T; Domoki F; Busija DW
J Cereb Blood Flow Metab; 2008 Dec; 28(12):1927-35. PubMed ID: 18665182
[TBL] [Abstract][Full Text] [Related]
17. Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs.
Satoh K; Takaguri A; Itagaki M; Kano S; Ichihara K
J Pharmacol Sci; 2008 Apr; 106(4):593-9. PubMed ID: 18403900
[TBL] [Abstract][Full Text] [Related]
18. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Engelhorn T; Doerfler A; Heusch G; Schulz R
Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
[TBL] [Abstract][Full Text] [Related]
19. Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension.
Matsuo S; Saiki Y; Adachi O; Kawamoto S; Fukushige S; Horii A; Saiki Y
J Thorac Cardiovasc Surg; 2015 Mar; 149(3):902-9. PubMed ID: 25454916
[TBL] [Abstract][Full Text] [Related]
20. Effects of rosuvastatin on ADMA, rhokinase, NADPH oxidase, caveolin-1, hsp 90 and NFkB levels in a rat model of myocardial ischaemia-reperfusion.
Burma O; Onat E; Uysal A; Ilhan N; Erol D; Ozcan M; Sahna E
Cardiovasc J Afr; 2014; 25(5):212-6. PubMed ID: 25629537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
